Discover how tildrakizumab, a novel interleukin-23 inhibitor, improves quality of life for patients with moderate to severe plaque psoriasis.
- Tuesday, May 12, 2026
Discover how tildrakizumab, a novel interleukin-23 inhibitor, improves quality of life for patients with moderate to severe plaque psoriasis.
